Zacks: Athenex Inc (ATNX) Given $25.73 Consensus Price Target by Analysts
Athenex Inc (NASDAQ:ATNX) has been given an average broker rating score of 2.00 (Buy) from the three analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Athenex’s rating score has declined by 33.3% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokers have set a one year consensus target price of $25.73 for the company, according to Zacks. Zacks has also assigned Athenex an industry rank of 101 out of 265 based on the ratings given to related companies.
Several brokerages have commented on ATNX. J P Morgan Chase & Co began coverage on Athenex in a research note on Wednesday, October 18th. They set a “neutral” rating and a $22.20 target price on the stock. Laidlaw began coverage on Athenex in a research note on Tuesday, September 19th. They set a “buy” rating and a $36.00 target price on the stock. Credit Suisse Group began coverage on Athenex in a research note on Monday, September 18th. They set an “outperform” rating and a $25.00 target price on the stock. Finally, Royal Bank of Canada began coverage on Athenex in a research note on Thursday, September 14th. They set an “outperform” rating and a $35.00 target price on the stock.
Several hedge funds have recently added to or reduced their stakes in ATNX. Laurion Capital Management LP purchased a new position in shares of Athenex in the 2nd quarter worth $1,600,000. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Athenex in the 3rd quarter worth $1,559,000. OxFORD Asset Management LLP purchased a new position in shares of Athenex in the 2nd quarter worth $956,000. California Public Employees Retirement System purchased a new position in shares of Athenex in the 2nd quarter worth $800,000. Finally, Vanguard Group Inc. purchased a new position in shares of Athenex in the 2nd quarter worth $800,000. Hedge funds and other institutional investors own 2.93% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/12/zacks-athenex-inc-atnx-given-25-73-consensus-price-target-by-analysts.html.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.